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Observational studies have reported either null or weak protective associations for coffee
consumption and risk of breast cancer.
Methods
We conducted a two-sample Mendelian randomization (MR) analysis to evaluate the rela-
tionship between coffee consumption and breast cancer risk using 33 single-nucleotide
polymorphisms (SNPs) associated with coffee consumption from a genome-wide associa-
tion (GWA) study on 212,119 female UK Biobank participants of White British ancestry. Risk
estimates for breast cancer were retrieved from publicly available GWA summary statistics
from the Breast Cancer Association Consortium (BCAC) on 122,977 cases (of which 69,501
were estrogen receptor (ER)-positive, 21,468 ER-negative) and 105,974 controls of Euro-
pean ancestry. Random-effects inverse variance weighted (IVW) MR analyses were per-
formed along with several sensitivity analyses to assess the impact of potential MR
assumption violations.
Results
One cup per day increase in genetically predicted coffee consumption in women was not
associated with risk of total (IVW random-effects; odds ratio (OR): 0.91, 95% confidence
intervals (CI): 0.80–1.02, P: 0.12, P for instrument heterogeneity: 7.17e-13), ER-positive
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(OR = 0.90, 95% CI: 0.79–1.02, P: 0.09) and ER-negative breast cancer (OR: 0.88, 95% CI:
0.75–1.03, P: 0.12). Null associations were also found in the sensitivity analyses using MR-
Egger (total breast cancer; OR: 1.00, 95% CI: 0.80–1.25), weighted median (OR: 0.97, 95%
CI: 0.89–1.05) and weighted mode (OR: 1.00, CI: 0.93–1.07).
Conclusions
The results of this large MR study do not support an association of genetically predicted cof-
fee consumption on breast cancer risk, but we cannot rule out existence of a weak
association.
Background
Coffee contains biochemical compounds such as caffeine, polyphenols and diterpenes that
may protect against breast cancer risk through their anticarcinogenic properties [1–3] or
through their favorable alterations of levels of estradiol and SHBG [4–8]. Several observational
studies have investigated the association between coffee consumption and breast cancer risk,
but findings have been inconsistent with the majority of studies reporting null associations [9–
25] and other studies reporting protective associations [26–30]. A recent meta-analysis includ-
ing 21 prospective cohort studies reported a weak protective association for highest versus low-
est category of coffee consumption with overall (RR = 0.96, 95% CI = 0.93–1.00) and
postmenopausal (RR = 0.92, 95% CI = 0.88–0.98) breast cancer [31]. However, observational
studies may be confounded by other dietary or lifestyle factors. Further, there are no clinical
trials on the effect of coffee consumption on breast cancer risk, and it is still unclear whether
an association exists and if so, whether it is causal.
Several genome-wide association studies (GWAS) on coffee or caffeine consumption have
been previously published [32–37]. One of these GWAS was a meta-analysis conducted by the
Coffee and Caffeine Genetics Consortium in 2015 incorporating summary statistics from 28
population-based studies of European ancestry, and reported six loci associated with coffee
consumption that were involved either in the pharmacokinetics (cytochrome P4501A1
(CYP1A1)/cytochrome P4501A2 (CYP1A2), aryl hydrocarbon receptor (AHR)) or pharmaco-
dynamics of caffeine (brain-derived neurotrophic factor (BDNF) and solute carrier family 6
member 4 (SLC6A4)) [35]. A more recent and larger GWAS was conducted among individu-
als (179,954 males and 212,119 females) of white British ancestry in the UK Biobank (UKB)
cohort [37], and identified 35 genetic variants strongly associated with coffee intake.
Mendelian randomization (MR) is a method that uses genetic variation arising from meio-
sis as a natural experiment, to investigate the potential causal relationship between an exposure
and an outcome [38, 39]. MR estimates are less susceptible to bias from potential reverse cau-
sality and confounding compared to estimates from observational studies, because genetic var-
iants are randomly distributed at conception [40, 41]. A recent MR study assessed the
potential causal association between coffee consumption and risk of several cancers, including
breast cancer, and concluded that coffee consumption is unlikely to be associated with overall
breast cancer susceptibility [37]. However, the latter study did not report associations by
breast cancer subtypes. In the current MR study, we investigated the relationship between
genetically predicted coffee consumption and risk of breast cancer overall as well as breast can-
cer subtypes incorporating several MR methods to assess the impact of potential MR assump-
tion violations.
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Methods
Genetic data on coffee consumption
We used 35 single nucleotide polymorphisms (SNPs) that were associated with coffee con-
sumption at genome-wide significance (p<5e-8) level in the combined population of men and
women in UKB [37], but their beta estimates (SNP-coffee) were derived from analyses only
among the female population. In a sensitivity analysis, we combined beta estimates (SNP-cof-
fee) for both men and women to increase statistical power. The UKB is a population-based
cohort study of more than 500,000 participants aged 38 to 73 years, who enrolled in the study
between 2006 and 2010 from across the UK [42]. Coffee consumption was measured via self-
administered questionnaires and was defined as cups of decaffeinated coffee, instant coffee,
ground coffee and any other type of coffee (UKB Data field ID: 1508) consumed per day [37].
Briefly, the UKB participants were genotyped using Affymetrix UK Biobank Axiom array and
imputed against the UK10K, 1000 Genomes Phase 3 and Haplotype Reference Consortium
panels [37]. The GWAS was conducted using the BOLT-LMM software [43] to model the
genetic association accounting for cryptic relatedness in the UKB sample. SNPs were clumped
at r2 <0.01 using a 10-mb window [37].
Genetic data on breast cancer
Out of the 35 genome-wide significant SNPs [37], we extracted 33 SNPs from the publicly
available breast cancer GWAS from the Breast Cancer Association Consortium (BCAC).
BCAC has data on 122,977 breast cancer cases of which 69,501 were estrogen receptor (ER)-
positive, 21,468 ER-negative, and 105,974 controls of European ancestry (http://bcac.ccge.
medschl.cam.ac.uk/bcacdata/oncoarray/gwas-icogs-and-oncoarray-summary-results/). BCAC
was initiated in 2005 and is an international collaboration that studies genetic susceptibility to
breast cancer. The breast cancer GWAS was performed in females of European ancestry from
68 studies collaborating in BCAC, the Discovery, Biology and Risk of Inherited Variants in
Breast Cancer Consortium (DRIVE; 61,282 cases and 45,494 controls), the Illumina iSelect
genotyping Collaborative Oncological Gene-Environment Study (iCOGS; 46,785 cases and
42,892 controls), and 11 other breast cancer GWAS (14,910 cases and 17,588 controls) [44].
Genotyping in the BCAC and DRIVE studies was done using OncoArray1, whereas iCOGS
used Illumina iSelect array (http://ccge.medschl.cam.ac.uk/research/consortia/icogs/). Using
the 1000 Genomes Project (Phase 3) reference panel, genotypes were imputed for approxi-
mately 21M variants [44].
Statistical power
Statistical power calculations were conducted using the online mRnd calculator (available at
http://cnsgenomics.com/shiny/mRnd/). Using an estimated 1% variance of coffee consump-
tion explained by the instruments [37], the study had 80% power with a type I error rate of
0.05 to detect associations of odds ratios of 0.89, 0.87 and 0.80 per one cup of coffee per day
and risk of overall, ER-positive and ER-negative breast cancer, respectively.
Statistical analysis
Main MR analysis. We conducted a two-sample MR using summary association data for
33 coffee-associated SNPs. We ran both fixed- and random-effects inverse-variance weighted
(IVW) models, but the random-effects IVW model was considered the main analysis due to
the large number of SNPs and the substantive observed heterogeneity [45, 46]. The IVW MR
approach combines individual MR estimates across SNPs to derive an overall weighted
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estimate of the potential causal effect. We calculated the MR-derived odds ratio (OR) of breast
cancer risk for a one cup per day increase in genetically predicted coffee consumption. This
study used publicly available data.
Sensitivity analyses. The IVW MR approach assumes that all genetic variants must satisfy
the instrumental variable assumptions, namely the genetic variants must be: 1) associated with
coffee consumption, 2) not associated with confounders of the association between coffee con-
sumption and breast cancer, and 3) only associated with breast cancer via their association
with coffee consumption [45, 47, 48]. We tested for potential violation of the first MR assump-
tion by measuring the strength of the genetic instruments using F-statistics. The F-statistic is
the ratio of the mean square of the model to the mean square of error [49]. The Cochran’s Q
test and the I2 statistic were used to quantify the heterogeneity in effect sizes between the
genetic instruments [50], which may indicate horizontal pleiotropy that could violate the third
MR assumption. To further test and attempt to correct for potential violation of the second
and third MR assumptions, we used several approaches such as the MR-Egger regression [51],
the weighted median [52] and mode [53] methods, and the MR pleiotropy residual sum and
outlier test (MR-PRESSO) [54].
MR-Egger. The MR-Egger is an adaption of Egger regression, which allows for directional
pleiotropy by introducing an intercept in the weighted regression model. Values away from
zero for the intercept term are an indication of horizontal pleiotropy [51]. The MR-Egger
approach provides unbiased results in the presence of pleiotropic instruments assuming that
the magnitude of pleiotropic effects is independent of the size of the SNP-coffee consumption
effects, which is called the Instrument Strength Independent of Direct Effects (InSIDE)
assumption [51].
Weighted median. We used the weighted median method that orders the MR estimates
obtained using each instrument weighted for the inverse of their variance. Selecting the
median result provides a single MR estimate with confidence intervals estimated using a
parametric bootstrap method [52]. The weighted median does not require that the size of any
pleiotropic effects on the instruments are uncorrelated to their effects on the intermediate phe-
notype, but assumes that at least half of the instruments are valid [55].
Weighted mode. The mode based causal estimate consistently estimates the true causal
effect when the largest group of instruments with consistent MR estimates is valid [53].
MR-PRESSO. We used the MR-PRESSO outlier test to identify outlier SNPs, which could
have pleiotropic effects [54]. This method regresses SNP-outcome on SNP-exposure and uses
square of residuals to identify outliers.
To further determine whether pleiotropy could have influenced our results, we collected
information on published associations of the genetic instruments for coffee consumption with
other phenotypes from the Phenoscanner webpage [56]. Genetic instruments associated at
genome-wide significance with potentially important confounders of the coffee and breast
cancer association, namely BMI [57–61], age at menarche [62, 63], alcohol [64–68], smoking
[67, 69–71] and age at menopause [72] were iteratively excluded from the analyses.
In addition, we repeated the analysis after excluding SNPs that had p-values in their associa-
tions with coffee consumption among women larger than 1e-05 to avoid weak instrument
bias. We also used beta estimates from a previous GWAS as an alternative instrument of eight
SNPs (rs1260326, rs1481012, rs17685, rs7800944, rs6265, rs9902453, rs2472297 and
rs4410790) associated with coffee consumption [35] to ensure that our results were robust
against different choices of instrument selection and because these eight SNPs are linked to
caffeine metabolism and may reflect less likelihood for pleiotropic actions. All the analyses
were performed using the MR robust package in Stata [73] and the Mendelian randomization
package in R [74].
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Results
The associations between the genetic instruments with coffee consumption and breast cancer
are shown in the S1 Table. One variant (rs17817964 in FTO) was strongly associated with over-
all (P = 4.67E-20), ER-positive (P = 2.48E-13) and ER-negative breast cancer (P = 1.56E-09).
Main MR analyses
The fixed-effects IVW method yielded inverse associations for genetically predicted coffee
intake and risk of total, ER-positive and ER-negative breast cancer (Figs 1–3 and S2 Table),
but there was substantial heterogeneity in the individual SNPs instrumenting coffee and risk
of disease (Cochran’s Q test P-value = 10−5–10−13, I2 = 57–74%, S1–S6 Figs). Therefore, the
random-effects IVW model was preferentially adopted for the main analysis, where the associ-
ation between coffee consumption (per cup of coffee per day) and total (OR = 0.91, 95%
CI = 0.80–1.02, P = 0.12), ER-positive (OR = 0.90, 95% CI = 0.79–1.02, P = 0.09) and ER-nega-
tive breast cancer (OR = 0.88, 95% CI = 0.75–1.03, P = 0.12) resulted in wider confidence inter-
vals overlapping the null (Figs 1–3 and S2 Table).
MR-Egger
Results based on the MR-Egger regression did not show any association for genetically pre-
dicted coffee consumption and risk of total breast cancer or subtypes (Figs 1–3, S2 Table).
Weighted median and mode
Similarly, results from the weighted median analysis showed little evidence of an association
per one cup of coffee per day and overall (OR = 0.97, 95% CI = 0.89–1.05, P = 0.45, Fig 1), ER-
positive (OR = 0.94, 95% CI = 0.86–1.04, P = 0.24, Fig 2) and ER-negative breast cancer
(OR = 1.02, 95% CI = 0.90–1.17, P = 0.72, Fig 3). The weighted mode model also yielded little
evidence for an association (Overall breast cancer; OR = 1.00, 95% CI = 0.93–1.07, Figs 1–3
and S2 Table).
MR-PRESSO
The MR-PRESSO outlier test detected six SNPs as potential outliers for total breast cancer (i.e.
rs13387939, rs17817964, rs34060476, rs2472297, rs2521501 and rs539515), three SNPs for ER-
positive breast cancer (i.e. rs17817964, rs2472297 and rs2521501) and three SNPs for ER-nega-
tive breast cancer (i.e. rs13387939, rs3810291 and rs17817964). After excluding these SNPs
outliers, there was an inverse association between genetically predicted coffee intake (per one
cup of coffee per day) and risk of overall (OR = 0.90, 95% CI = 0.83–0.98, P = 0.03) and ER-
positive breast cancer (OR = 0.87, 95% CI = 0.78–0.97, P = 0.02), but no association for ER-
negative breast cancer (OR = 0.97, 95% CI = 0.87–1.08, P = 0.62, S2 Table). However, the
rs2472297 is located between CYP1A1 and CYP1A2 and is involved in the pharmacokinetics of
caffeine, and has the strongest association with coffee consumption amongst all genetic instru-
ments (P< 1e-168). Many of the other outlying SNPs had genome-wide significant associations
with age at menarche (rs17817964, rs13387939, rs539515 and rs3810291), body mass index
(rs17817964, rs13387939, rs2472297, rs539515 and rs3810291) and alcohol intake (rs17817964
and rs34060476, S3 Table).
Sensitivity analyses
We performed several sensitivity analyses and there was little evidence of any association
between genetically predicted coffee consumption and breast cancer risk (S2 Table). We
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performed MR-analyses after excluding genetic instruments known to be associated at
genome-wide significance with 1) body mass index (i.e. rs4357572, rs539515, rs62106258,
rs13387939, rs142219, rs2465054, rs4410790, rs2472297, rs17817964, rs66723169 and
rs3810291), 2) age at menarche (i.e. rs539515, rs62106258, rs13387939, rs2236955, rs17817964
and rs381029), 3) alcohol consumption (i.e. rs1260326, rs34060476, rs17817964 and
rs66723169), 4) smoking (i.e. rs56113850), and 5) age at menopause (i.e. rs1260326) (S2 and
S3 Tables). When we reran the analyses after excluding 13 genetic instruments (i.e.
Fig 1. Association between 1 cup/day increase of coffee consumption and breast cancer risk overall. MR-analyses are derived using random effect
IVW, MR-Egger, weighted median and mode.
https://doi.org/10.1371/journal.pone.0236904.g001
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rs117968677, rs1260326, rs1422191, rs16966903, rs2236955, rs2465054, rs2667773,
rs34190000, rs3810291, rs395815, rs4092465, rs55754437 and rs62064918) with p-values with
coffee consumption among women larger than 10−5, the results remained largely the same
(Overall; OR = 0.90, 95% CI 0.77–1.06, ER-positive; OR = 0.99, 95% CI 0.77–1.05 and ER-neg-
ative; OR = 0.88, 95% CI 0.72–1.07, S2 Table). In another sensitivity analysis, we used as
genetic instruments eight SNPs (i.e. rs1260326, rs1481012, rs17685, rs7800944, rs6265,
rs9902453, rs4410790 and rs2472297) from a GWAS for coffee consumption among
Fig 2. Association between 1 cup/day increase of coffee consumption and risk of ER-positive breast cancer. MR-analyses are derived using random
effect IVW, MR-Egger, weighted median and mode.
https://doi.org/10.1371/journal.pone.0236904.g002
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consumers conducted by the Coffee and Caffeine Genetics Consortium [35], and there was
again no evidence of an association (Overall; OR = 1.10, 95% CI 0.97–1.24, ER-positive;
OR = 1.07, 95% CI 0.96–1.21 and ER-negative; OR = 1.16, 95% CI 0.97–1.38). To increase sta-
tistical power, we used the 33 genetic instruments from UK Biobank but with beta estimates
(SNP-coffee) from females and males combined, but the results remained largely the same
(Overall; OR = 0.92, 95% CI 0.82–1.04, P = 0.20, ER-positive; OR = 0.92, 95% CI 0.81–1.04,
P = 0.16, ER-negative; OR = 0.90, 95% CI 0.77–1.05, P = 0.17, S2 Table).
Fig 3. Association between 1 cup/day increase of coffee consumption and risk of ER-negative breast cancer. MR-analyses are derived using random
effect IVW, MR-Egger, weighted median and mode.
https://doi.org/10.1371/journal.pone.0236904.g003
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Discussion
In this comprehensive MR analysis of coffee consumption with risk of breast cancer, we
observed that in the majority of analyses genetically predicted consumption of coffee was not
associated with overall, ER-positive and ER-negative breast cancer. In line with our results, a
recent large MR-study on the association between coffee consumption and risk of being diag-
nosed with or dying from cancer overall and by anatomical subsite reported no evidence for
an association with risk of breast cancer [37]. Compared to the previous study, our study
added results by ER-status and presented detailed sensitivity analyses to fully assess potential
violations of MR assumptions.
Coffee is among the most commonly consumed beverages worldwide, and its drinking pro-
vides exposure to a range of biologically active compounds [75]. Higher coffee consumption
has been associated with decreased risk of all-cause, cardiovascular and cancer mortality
among non-smokers [76]. Several observational studies have investigated the association
between coffee consumption and risk of breast cancer development, but findings have been
inconsistent [31, 77, 78]. The most recent meta-analysis synthesized evidence from 21 prospec-
tive cohort studies [31], and reported a weak inverse association between coffee consumption
and risk of total (OR higher vs. lower = 0.96, 95% CI = 0.93–1.00) and postmenopausal breast
cancer (OR = 0.92, 95% CI = 0.88–0.98). Null associations were reported by estrogen or pro-
gesterone receptor status [31]. When a dose-response meta-analysis was conducted among 13
prospective studies [31], the association per one cup of coffee per day was nominally signifi-
cant (OR for postmenopausal disease = 0.97, 95% CI = 0.95–1.00), which was consistent with
the finding of the current MR study (OR = 0.90, 95% CI 0.79–1.02). In agreement, the World
Cancer Research Fund Third Expert Report graded the evidence of coffee consumption and
breast cancer risk as limited-no conclusion [79].
MR studies can be useful in nutritional epidemiology, as they are less susceptible to biases
that are commonly present in traditional observational literature [80], namely exposure mea-
surement error, residual confounding and reverse causation. MR estimates warrant a causal
interpretation only if the assumptions of the instrumental variable approach hold. Though it is
not possible to prove the validity of the assumptions in entirety, we performed several sensitiv-
ity analyses to detect potential violations and derived estimates that are potentially robust
against violations of these assumptions. The majority of the sensitivity analyses supported our
main analysis finding.
Several limitations should be considered when interpreting our findings. Our MR-analysis
had appropriate statistical power to detect an OR of 0.89 per cup of coffee per day and risk of
overall breast cancer. Observational studies have detected smaller associations of coffee con-
sumption and breast cancer risk than this [31]. We were unable to rule out the possibility that
coffee consumption may have a weaker association that we were not powered to detect. A
weakness of using summary level data in two-sample MR is that stratified analyses by covari-
ates of interest (e.g. smoking, alcohol, obesity, physical activity) are not possible which would
have allowed us to investigate potential interactions between risk factors, but previous observa-
tional studies have in general not identified interactions with these variables [31]. Although we
have involved clinically meaningful disease subtypes such as ER+ /− breast cancer, we could
not examine breast cancer based on menopause status but 85% of breast cancer cases in our
sample are postmenopausal. Although our genetic instruments are robustly associated with
coffee consumption, coffee consumption itself is a heterogeneous phenotype that may poten-
tially limit the generalizability of our findings on specific coffee type or preparation procedure.
In addition, we are currently unable to isolate and classify genetic variants into caffeine and
non-caffeine aspects of coffee given that the genetic loci heavily overlap, and future research
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into the biological mechanisms of the genetic instruments is warranted when more data
becomes available; until then, a potential role of micronutrients attained through coffee con-
sumption on reduction of breast cancer risk cannot be ruled out. Another limitation was that
two-sample MR assumes linearity, so we could not evaluate potential existence of non-linear
associations.
Conclusions
In summary, the results of this large MR study do not support an association of genetically pre-
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